Latest Breaking News On - Cti biopharma corp - Page 16 : comparemela.com

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to six new.

United statesMaeve conneighton maghan meyersCompensation committeeBiopharma corpIncentive planNasdaq listing ruleGrant datePharma investorCti biopharma corpஒன்றுபட்டது மாநிலங்களில்இழப்பீடு குழுஊக்கத்தொகை திட்டம்நாஸ்டாக் பட்டியல் ஆட்சிமானியம் தேதிபார்மா முதலீட்டாளர்

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) News provided by Share this article Share this article SEATTLE, May 12, 2021 /PRNewswire/ CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees acceptance of employment with the company. The equity awards were approved on May 12, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received options to purchase an aggregate of 90,000 shares of CTI BioPharma common stock. The options will be issued upon each employee s commencement of employment (the Grant Date ), and all stock options included within the equity inducement awards will have an exercise price equal to the clos

United statesMaeve conneighton maghan meyersCompensation committeeBiopharma corpIncentive planNasdaq listing ruleGrant datePharma investorCti biopharma corpஒன்றுபட்டது மாநிலங்களில்இழப்பீடு குழுஊக்கத்தொகை திட்டம்நாஸ்டாக் பட்டியல் ஆட்சிமானியம் தேதிபார்மா முதலீட்டாளர்

CTI BioPharma to Report First Quarter 2021 Financial Results on June 1, 2021

CTI BioPharma to Report First Quarter 2021 Financial Results on June 1, 2021
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United statesBiopharma corpPharma investor contactsCti biopharmaCti biopharma corpFinancial resultsManagement teamஒன்றுபட்டது மாநிலங்களில்பார்மா முதலீட்டாளர் தொடர்புகள்

CTI BioPharma Corp Announces Pricing of its Public Offering of Common Stock and Preferred Stock

Share this article Share this article SEATTLE, March 31, 2021 /PRNewswire/ CTI BioPharma Corp. (Nasdaq: CTIC) ( CTI ), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced the pricing of its previously announced underwritten public offering of 14,260,800 shares of its common stock and 600 shares of its series X 1 preferred stock (the Series X 1 Preferred ). In addition, CTI has granted the underwriters a 30-day option to purchase up to an additional 2,139,120 shares of its common stock on the same terms and conditions. The offering price to the public of a share of common stock is $2.50 and the offering price to the public of a share of Series X

United statesSan franciscoMaeve conneighton maghan meyersExchange commissionProspectus departmentNicolaus company incorporatedSecurities exchangeBiopharma corpSecurities actSecurities exchange actPrivate securities litigation reform actPharma investor contactsCti biopharma corpHealth care amp hospitalsMedical pharmaceuticalsStock offering

CTI BioPharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2020 financial results on Wednesday, March 17, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

Cti biopharmaCti biopharma corp